Ingram Micro Cloud Publishes Cloud Technology: The State of MSPs Report Aimed at Guiding Reseller Success
New Report provides key recommendations to MSPs on how to best grow their cloud businesses…
New Report provides key recommendations to MSPs on how to best grow their cloud businesses…
– Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected…
– Publication describing a novel technology that provides for very low levels of expression of…
Poster presentation to feature research involving niclosamide as a potential treatment for mild-to-moderate ulcerative proctitis…
RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today…
Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery…
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical…
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3…
Tilray to Acquire Hexo Corp.’s Senior Secured Convertible Notes Commercial and financial alliance would bring…
CHATHAM, N.J., March 03, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix…
PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the…
Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial…
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six…
– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration…
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn)…
BOSTON and LONDON, March 03, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE® growth and the 2021 launches…
Leuven, BELGIUM, Boston, MA, US – MARCH 3, 2022 – 08:00 AM CET – Oxurion…